Tag: CD79b
FDA Approves Polatuzumab Vedotin Combination With R-CHP for People With Certain...
The U.S. Food and Drug Administration (FDA) has approved polatuzumab vedotin-piiq Polivy®; Genentech/Roche)* in combination with rituximab (Rituxan®; Genetech/Biogen), cyclophosphamide, doxorubicin and prednisone (R-CHP) for the treatment of adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of two or greater.
Polatuzumab Vedotin Shows Complete Response in R/R Diffuse Large B-cell Lymphoma
Polatuzumab vedotin (Polivy™; Genentech/Roche) in combination with bendamustine (Treanda®; Cephalon/Teva Pharmaceutical) and rituximab (Rituxan®; Genentech/Roche) shows encouraging rates of complete response (CR) among patients...
Phase I Study Supports Therapeutic Potential of Polatuzumab Vedotin in non-Hodgkin...
Lymphoma - with its main forms Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) - is the most common blood cancer which occurs when cells...
